Zalutumumab in head and neck cancer

Expert Opinion on Biological Therapy

Volumn 12, Issue 1, 2012, Pages 119-125

  Schick, Ulrike ^a,b   Gujral, Dorothy M ^a   Richards, Tom M ^a   Harrington, Kevin J ^a,b   Nutting, Christopher M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

EGFR; Head and neck cancer; Monoclonal antibodies; Zalutumumab

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; METHOTREXATE; PLATINUM DERIVATIVE; ZALUTUMUMAB;

ADVANCED CANCER; ANAPHYLAXIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; COMORBIDITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEVER; HEAD AND NECK CANCER; HEADACHE; HOT FLUSH; HUMAN; HYPOMAGNESEMIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; RIGOR; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SWEATING;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; MICE; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84055184263     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.643864     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E Murray T, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
2. Hauswald H, Simon C, Hecht S, et al. Long-term outcome and patterns of failure in patients with advanced head and neck cancer. Radiat Oncol 2011;6:70
3. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000;88:876-83 (Pubitemid 30091108)
4. Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications. Radiat Oncol 2006;1:11
5. Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005;41:453-60 (Pubitemid 40187218)
6. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6 This is an important report showing that EGFR expression correlates with poor prognosis and survival rates. (Pubitemid 46622295)
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78 A key paper supporting the addition of cetuximab to radiotherapy in the treatment of locally advanced SCCHN. (Pubitemid 43209104)
8. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8 This paper analysed the relationbetween rash and survival in patients treated with cetuximab and radiotherapy for SCCHN.
9. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27. This large randomized trial investigated the benefit of adding cetuximab to platinum-fluorouracil-based chemotherapy in previoulsy untreated recurrent or metastatic SCCHN.
10. Schilder RJ, Pathak HB, Lokshin AE, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009;113:21-7
11. Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011;29:2312-18
12. Merchan JR, Ferrell A, Macintyre J, et al. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am J Clin Oncol 2011;published online 5 May 2011; doi: 10.1097/COC.0b013e31821862fb
13. Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009;100:298-304
14. Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009;20:1596-603
15. Schiller JH, von Pawel J, Schutt P, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1977-85
16. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-8 (Pubitemid 47312862)
17. Wainberg ZA, Hecht JR. Panitumumab in colorectal cancer. Expert Rev Anticancer Ther 2007;7:967-73 (Pubitemid 47180897)
18. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study. Ann Oncol 2010;21:2213-19
19. You B, Brade A, Magalhaes JM, et al. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 2011;29:996-1003
20. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010;21:342-7
21. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54 (Pubitemid 41079803)
22. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: The age of the Umabs. Biotechnol J 2008;3:1157-71
23. Lammerts van Bueren JJ, Bleeker WK, Brannstrom A, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 2008;105:6109-14. This paper focuses on the recent advances in the knowledge of mechanism of action of zalutumumab. (Pubitemid 351758407)
24. Kastner J, Loeffler HH, Roberts SK, et al. Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics. J Struct Biol 2009;167:117-28
25. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action. Cancer Res 2006;66:7630-8 (Pubitemid 44289220)
26. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual mode of Zalutumumab 124 Expert Opin. Biol. Ther. (2012) 12(1) action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004;173:4699-707
27. Overdijk MB, Verploegen S, van den Brakel JH, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011;187:3383-90. This study analyses the mechanism of action of EGFR mAbs, especially ADCC induction.
28. Bastholt L, Specht L, Jensen K, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007;85:24-8. This is the first trial, to our knowledge, designed to evaluate safety, pharmacokinetics and clinical efficacity of zalutumumab in refractory head and neck cancer. (Pubitemid 47562580)
29. Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomized phase III trial. Lancet Oncol 2011;12:333-43. This is the first controlled study, to our knowledge, to show that an EGFR-targeted antibody induces a clinically meaningful improvement in progression-free survival in patients presenting with non curable metastatic or recurrent SCCHN who have failed platinum-based chemotherapy.
30. Noordhuis MG, Eijsink JJ, Ten Hoor KA, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 2009;15:7389-97
31. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7 (Pubitemid 46954639)
32. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87
33. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77
34. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007;25:3644-8 (Pubitemid 47372602)
35. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358:1109-17 (Pubitemid 351398485)
36. Rivera F, Salcedo M, Vega N Blanco Y, Lopez C. Current situation of zalutumumab. Expert Opin Biol Ther 2009;9:667-74 This article gives a detailed overview of zalutumumab in different clinical settings.
37. Van Walle I, Gansemans Y, Parren PW, et al. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007;7:405-18 (Pubitemid 46383483)